At the EADV 2026 Congress, AbbVie shared encouraging Phase 2 data on Zumilokibart, showing significant improvements in atopic dermatitis treatment.

Reported Wednesday, Sep 30 - 5:52am EDT (TheFly subscription required to read more.)

Apogee Therapeutics said on Wednesday it secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support ​late-stage development and potential commercialization of its experimental eczema drug, ‌zumilokibart.

Click to view the official SEC document.

AbbVieは2026年9月3日、Apogee Therapeuticsの買収完了を発表した。取得したzumilokibart（IL-13標的抗体）の第2相結果やAPG273併用療法の位置付け、財務影響を整理する。

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for...

Apogee Therapeutics’ Phase 2 data show zumilokibart maintains strong skin clearance and itch relief in moderate-to-severe eczema for 52 weeks with dosing every 3 or 6 months.

Apogee's eczema drug zumilokibart shows strong maintenance data with dosing every 3-6 months, outperforming benchmarks set by Sanofi/Regeneron's Dupixent.

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis

Apogee's eczema drug zumilokibart shows strong maintenance data with dosing every 3-6 months, outperforming benchmarks set by Sanofi/Regeneron's Dupixent.

Reported Monday, Mar 23 - 8:29am EDT (TheFly subscription required to read more.)

Reported Monday, Mar 23 - 8:13am EDT (TheFly subscription required to read more.)

Reported Tuesday, Jan 6 - 6:10am EST (TheFly subscription required to read more.)

Apogee’s lead candidate zumilokibart, an IL-13 inhibitor also called APG777, is a long-acting treatment that, according to the company, holds “pipeline-in-a-product potential” because of the opportunity it has for treating a variety of immunology and inflammation (I&I) diseases for which the drug is under study. The post AbbVie to Acquire Apogee Therapeutics for $10.9B appeared first on GEN - Genetic Engineering and Biotechnology News .

Investing.com -- Apogee Therapeutics Inc (NASDAQ:APGE) stock fell 4% in premarket trading Tuesday after the company announced interim results from a Phase 1b trial of its zumilokibart (APG777) treatment in asthma patients. The clinical-stage biotechnology company reported that zumilokibart demonstrated a favorable safety profile and durable suppression of FeNO, a biomarker of Type 2 inflammation, through 16 weeks for all patients in the trial. For patients with available follow-up data, the suppression continued through 32 weeks, supporting potential for 3- or 6-month dosing. Despite these positive findings, investors appeared to react cautiously to the data, which came from a small sample size of 19 adult patients with mild-to-moderate asthma. The company highlighted that the treatment showed a maximum absolute mean FeNO reduction of 45 ppb (60% decrease from baseline) after a single dose. No serious adverse events were reported, with gastroesophageal reflux disease being the only treatment-emergent adverse event observed in more than one patient. Apogee is advancing zumilokibart beyond dermatology applications, positioning it as what the company calls a "pipeline-in-a-product" with potential across inflammatory and immunology indications. The company is also progressing the treatment in atopic dermatitis with Phase 2 APEX trials, aiming to initiate Phase 3 studies by the end of 2026. The company reported a strong cash position of $913 million with runway extending into the second half of 2028, supporting advancement toward a potential launch of zumilokibart in 2029. Apogee expects multiple clinical data readouts in 2026, including results from its Phase 2 APEX trials in atopic dermatitis and its Phase 1b trial of APG279, a combination therapy being tested against Dupixent. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ProPicks AI evaluates APGE alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if APGE is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

AbbVie Strikes an All-Cash Deal   AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash transaction worth roughly $10.9 billion.